Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Completed

• Conditions: Age-related Macular Degeneration (AMD)
• Interventions: Other: All participants

• Registration Number: NCT05066685
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Detailed Description

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program.

PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020.

* Identification period of the index period: 10/10/2019 to 04/30/2020

* Index date: Date of enrollment in the PSS program

* Study Period: 10/10/2019 to 04/30/2020

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2020-08-11
• Primary Completion: 2020-09-25
• Study Completion: 2020-09-25
• Study First Submitted: 2021-09-23
• Study First Submitted QC: 2021-09-23
• Status Verified: 2021-10
• Study First Posted: 2021-10-04
• Last Update Submitted: 2021-10-06
• Last Update Posted: 2021-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18457

Inclusion Criteria

• Patients were enrolled in the brolucizumab PSS program
• ≥19 years old

Read More

Exclusion Criteria

• None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
All Participants	All participants	All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program

Primary Outcome Measures

Name	Time	Method
Number of patients with Primary plan type	Index date defined as the date of enrollment in the PSS program	The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance.

Secondary Outcome Measures

Name	Time	Method
Disease Status	Index date defined as the date of enrollment in the PSS program	The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral
Gender	Index date defined as the date of enrollment in the PSS program	Gender information of patients enrolled in the brolucizumab PSS program was reported
Age	Index date defined as the date of enrollment in the PSS program	Age information of patients enrolled in the brolucizumab PSS program was reported
Patient region (by state)	Index date defined as the date of enrollment in the PSS program	Distribution of patients across US states
Provider region (by state)	Index date defined as the date of enrollment in the PSS program	Number of providers and their distribution across US states
Insurance coverage	Index date defined as the date of enrollment in the PSS program	The insurance coverage details for all the patients with wet AMD was reported
Number of patients with Secondary plan type	Index date defined as the date of enrollment in the PSS program	The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance

Trial Locations

Locations (1)

Novartis Investigative Site; 🇺🇸 East Hanover, New Jersey, United States